South African COVID-19 Corona Virus Resource Portal: www.sacoronavirus.co.za

COVID 19: Information Cancer patients should know. 
View information and infographic.

MOTIVATION FOR: PROMPT APPROVAL OF TRASTUZUMAB BIOSIMILARS TO PROMOTE COMPETITION IN THE MARKET

17 July 2019: Cancer Alliance submits a motivation to SAHPRA for the prompt approval of trastuzumab biosimilars to promote competition in the market.

The Cancer Alliance of South Africa submits this memorandum in support of its request that SAHPRA promptly register biosimilars of the breast cancer medicine trastuzumab
for which manufacturers have submitted New Medicine Launch Forms. We commend SAHPRA for recently approving Mylan’s biosimilar and stress the importance of swiftly
approving the four remaining applications submitted by other trastuzumab biosimilar manufacturers.

Read the full report:

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

LETS FIGHT TOGETHER

drop us a line